Page last updated: 2024-08-22

cladribine and Blood Diseases

cladribine has been researched along with Blood Diseases in 15 studies

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (40.00)18.2507
2000's7 (46.67)29.6817
2010's2 (13.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abughanimeh, O; Bahaj, W; Foxworth, J; Gaur, R; Qasrawi, A; Qasrawi, L1
Alla, CA; Arbion, F; Blouin, P; Colombat, P; Donadieu, J; Eitenschenck, L; Emile, JF; Machet, MC; Pagnier, A; Plantaz, D; Yvert, M1
Hamaki, T; Heike, Y; Hori, A; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Kusumi, E; Masuo, S; Miyakoshi, S; Mori, S; Morinaga, S; Murashige, N; Muto, Y; Takaue, Y; Taniguchi, S; Tanosaki, R; Ueyama, J; Yuji, K1
Blonski, JZ; Gora-Tybor, J; Kasznicki, M; Robak, T; Smolewski, P; Urbanska-Rys, H1
Faoro, LN; Mesa, RA; Tefferi, A1
Baran, W; Dmoszyńska, A; Grosicki, S; Hellmann, A; Hołowiecki, J; Kiebiński, M; Krawczyńska, A; Kuliczkowski, K; Kyrcz-Krzemień, S; Lech-Marańda, E; Mazur, G; Pluta, A; Robak, T; Wach, M; Wawrzyniak, E; Wierzbowska, A; Wrzesień-Kuś, A1
Bernard, F; Bertrand, Y; Chastagner, P; Colin, VM; Donadieu, J; Landman Parker, J; Munzer, M; Ouache, M; Perel, Y; Thomas, C; Vermylen, C1
Ballabeni, P; Cerny, T; Fey, M; Hess, U; Laurencet, F; Luthi, JM; Plancherel, C; Rufener, B; Zulian, GB1
Bryson, HM; Sorkin, EM1
Komarnicki, M; Rasińska, M1
Baltz, JK; Montello, MJ1
Larson, RA; Mick, R; O'Brien, SM; Ratain, MJ; Spielberger, RT1
Bosly, A; Delannoy, A; Ferrant, A; Filleul, B; Martiat, P; Michaux, JL; Mineur, P; Montfort, L; Straetmans, N; Van Den Neste, E; Vandercam, B1
Błasińska-Morawiec, M; Błoński, JZ; Robak, T; Skotnicki, AB; Urbańska-Ryś, H1
Balzarotti, M; Bonadonna, G; De Paoli, A; Luoni, M; Rampinelli, I; Santoro, A; Tondini, C; Valagussa, P1

Reviews

5 review(s) available for cladribine and Blood Diseases

ArticleYear
Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?
    Annals of hematology, 2019, Volume: 98, Issue:3

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Interactions; Heart Diseases; Hematologic Diseases; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Liposomes; Meta-Analysis as Topic; Mucositis; Multicenter Studies as Topic; Neoplasms, Second Primary; Remission Induction; Survival Rate; Treatment Outcome

2019
Juvenile xanthogranuloma with hematological dysfunction treated with 2CDA-AraC.
    Pediatric blood & cancer, 2010, Volume: 55, Issue:4

    Topics: Cladribine; Cytarabine; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Infant; Male; Xanthogranuloma, Juvenile

2010
Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.
    Drugs, 1993, Volume: 46, Issue:5

    Topics: Animals; Cladribine; Hematologic Diseases; Humans; In Vitro Techniques; Leukemia; Lymphoma

1993
[Use of 2-chloro-2'-deoxyadenosine (2-CdA) in therapy of hematologic diseases].
    Polskie Archiwum Medycyny Wewnetrznej, 1993, Volume: 90, Issue:1

    Topics: Cladribine; Hematologic Diseases; Humans

1993
Cladribine for the treatment of hematologic malignancies.
    Clinical pharmacy, 1993, Volume: 12, Issue:11

    Topics: Cladribine; Clinical Trials as Topic; Hematologic Diseases; Humans; In Vitro Techniques; Leukemia; Models, Biological

1993

Trials

5 trial(s) available for cladribine and Blood Diseases

ArticleYear
Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Hematologic Diseases; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Opportunistic Infections; Remission Induction; Rituximab; Salvage Therapy; Survival Analysis

2004
A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Po
    Annals of hematology, 2005, Volume: 84, Issue:9

    Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Analysis

2005
The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
    Acta haematologica, 2007, Volume: 117, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Hematologic Diseases; Humans; Immunocompromised Host; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms, Second Primary; Prednisone; Prospective Studies; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome

2007
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Chi-Square Distribution; Cladribine; Diarrhea; Digestive System Diseases; Drug Administration Schedule; Fatigue; Female; Fever; Hematologic Diseases; Humans; Immunocompromised Host; Infections; Infusions, Intravenous; Logistic Models; Lymphoproliferative Disorders; Male; Middle Aged; Treatment Outcome

1996
Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Confidence Intervals; Cross-Over Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Vidarabine

2000

Other Studies

5 other study(ies) available for cladribine and Blood Diseases

ArticleYear
Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.
    Bone marrow transplantation, 2004, Volume: 33, Issue:7

    Topics: Adult; Aged; Antilymphocyte Serum; Bone Marrow Transplantation; Cladribine; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation Immunology; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2004
Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia.
    European journal of haematology, 2005, Volume: 74, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Hematologic Diseases; Hepatomegaly; Humans; Male; Middle Aged; Palliative Care; Primary Myelofibrosis; Retrospective Studies; Splenectomy

2005
Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction.
    European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:17

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cladribine; Cytarabine; Drug Therapy, Combination; Female; Hematologic Diseases; Histiocytosis, Langerhans-Cell; Humans; Infant; Infusions, Intravenous; Male; Pilot Projects; Survival Analysis

2005
Infectious complications after 2-chlorodeoxyadenosine therapy.
    European journal of haematology, 1996, Volume: 56, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cladribine; Cohort Studies; Disease Susceptibility; Female; Fever; Hematologic Diseases; Herpesviridae Infections; Humans; Immunologic Deficiency Syndromes; Incidence; Infections; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Retrospective Studies; Risk Factors; Waldenstrom Macroglobulinemia

1996
2-Chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger.
    Leukemia, 1999, Volume: 13, Issue:4

    Topics: Adult; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cladribine; Cyclophosphamide; Doxorubicin; Drug Eruptions; Drug Resistance, Neoplasm; Female; Fever; Hematologic Diseases; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome; Vincristine

1999